Mepindolol sulfate in the hyperkinetic heart syndrome.
In a single-blind test vs placebo in two crossover therapy phases, each lasting 4 weeks, it was shown in six clinical cases of hyperkinetic heart syndrome that 2 X 2.5 mg mepindolol sulfate daily is able to (1) lower significantly the HR and the systolic BP at rest and during exercise on the ergometer, (2) normalize or increase by 100% the restricted effective working capacity, and (3) improve the subjective symptoms. Mepindolol sulfate can accordingly be regarded as an effective therapeutic agent in hyperkinetic heart syndrome.
D000328:Adult; D004341:Drug Evaluation; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D009449:Neurocirculatory Asthenia / Q000188:drug therapy*; D010869:Pindolol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
C015340:mepindolol; D010869:Pindolol